Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice

Common features in insulin-resistance diabetes include inflammation and liver damage due to bile acid accumulation. This study aimed to test pharmacological effects of combining two drugs, ursodeoxycholic acid that has bile acid regulatory effects, and probucol (PB) that has potent anti-oxidative st...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic delivery 2019-09, Vol.10 (9), p.563-571
Main Authors: Mooranian, Armin, Zamani, Nassim, Takechi, Ryu, Al-Sallami, Hesham, Mikov, Momir, Goločorbin-Kon, Svetlana, Kovacevic, Bozica, Arfuso, Frank, Al-Salami, Hani
Format: Article
Language:English
Subjects:
Acids
Bile
Bile acids
Diabetes mellitus
Insulin
Insulin resistance
insulin-resistance diabetes
Interleukin 10
Liver
nanoencapsulation
Nanoparticles
Oxidative stress
poly(meth)acrylate
primary bile acid
probucol
Tumor necrosis factor-TNF
Urine
Ursodeoxycholic acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Common features in insulin-resistance diabetes include inflammation and liver damage due to bile acid accumulation. This study aimed to test pharmacological effects of combining two drugs, ursodeoxycholic acid that has bile acid regulatory effects, and probucol (PB) that has potent anti-oxidative stress effects, using a new poly(meth)acrylate nano-targeting formulation on prediabetic mice. Mice were made diabetic and were fed daily with either PB, nanoencapsulated PB or nanoencapsulated PB-ursodeoxycholic acid before blood, tissues, urine and feces were collected for inflammation and bile acid measurements. The nanoencapsulated PB-ursodeoxycholic acid formulation increased plasma IL-10, and increased the concentration of primary bile acids in the liver and heart. Results suggest potential applications in regulating IL-10 in insulin-resistance prediabetes.
ISSN:2041-5990
2041-6008
DOI:10.4155/tde-2019-0052